Università de Roma La Sapienza-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples

    British Journal of Cancer, Vol. 126, Núm. 12, pp. 1783-1794

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

2016

  1. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease

    Oncotarget, Vol. 7, Núm. 31, pp. 49194-49216

2012

  1. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease

    Modern Pathology, Vol. 25, Núm. 4, pp. 576-589

2004

  1. The role of ribavirin in the combination therapy of hepatitis C virus infection

    Current Pharmaceutical Design, Vol. 10, Núm. 17, pp. 2081-2092